[1]
Bridgeman MB, Abazia DT. Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. P & T : a peer-reviewed journal for formulary management. 2017 Mar:42(3):180-188
[PubMed PMID: 28250701]
[2]
Zias J, Stark H, Sellgman J, Levy R, Werker E, Breuer A, Mechoulam R. Early medical use of cannabis. Nature. 1993 May 20:363(6426):215
[PubMed PMID: 8387642]
[3]
McPartland JM, Agraval J, Gleeson D, Heasman K, Glass M. Cannabinoid receptors in invertebrates. Journal of evolutionary biology. 2006 Mar:19(2):366-73
[PubMed PMID: 16599912]
[5]
Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA. Cannabis and Cannabinoids for Chronic Pain. Current rheumatology reports. 2017 Oct 5:19(11):67. doi: 10.1007/s11926-017-0693-1. Epub 2017 Oct 5
[PubMed PMID: 28983880]
[6]
Sohler NL, Starrels JL, Khalid L, Bachhuber MA, Arnsten JH, Nahvi S, Jost J, Cunningham CO. Cannabis Use is Associated with Lower Odds of Prescription Opioid Analgesic Use Among HIV-Infected Individuals with Chronic Pain. Substance use & misuse. 2018 Aug 24:53(10):1602-1607. doi: 10.1080/10826084.2017.1416408. Epub 2018 Jan 17
[PubMed PMID: 29338578]
[7]
Morano A, Fanella M, Albini M, Cifelli P, Palma E, Giallonardo AT, Di Bonaventura C. Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects. Neuropsychiatric disease and treatment. 2020:16():381-396. doi: 10.2147/NDT.S203782. Epub 2020 Feb 7
[PubMed PMID: 32103958]
[8]
Badowski ME, Yanful PK. Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Therapeutics and clinical risk management. 2018:14():643-651. doi: 10.2147/TCRM.S126849. Epub 2018 Apr 6
[PubMed PMID: 29670357]
[9]
Abi-Jaoude E, Chen L, Cheung P, Bhikram T, Sandor P. Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome. The Journal of neuropsychiatry and clinical neurosciences. 2017 Fall:29(4):391-400. doi: 10.1176/appi.neuropsych.16110310. Epub 2017 May 3
[PubMed PMID: 28464701]
[10]
Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Current neurology and neuroscience reports. 2018 Feb 13:18(2):8. doi: 10.1007/s11910-018-0814-x. Epub 2018 Feb 13
[PubMed PMID: 29442178]
Level 1 (high-level) evidence
[11]
May MB, Glode AE. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. Cancer management and research. 2016:8():49-55. doi: 10.2147/CMAR.S81425. Epub 2016 May 12
[PubMed PMID: 27274310]
[12]
Calignano A, La Rana G, Loubet-Lescoulié P, Piomelli D. A role for the endogenous cannabinoid system in the peripheral control of pain initiation. Progress in brain research. 2000:129():471-82
[PubMed PMID: 11098711]
[13]
Castellano C, Rossi-Arnaud C, Cestari V, Costanzi M. Cannabinoids and memory: animal studies. Current drug targets. CNS and neurological disorders. 2003 Dec:2(6):389-402
[PubMed PMID: 14683467]
Level 3 (low-level) evidence
[14]
Rodríguez de Fonseca F, Del Arco I, Martín-Calderón JL, Gorriti MA, Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiology of disease. 1998 Dec:5(6 Pt B):483-501
[PubMed PMID: 9974180]
[15]
Gómez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodríguez de Fonseca F. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2002 Nov 1:22(21):9612-7
[PubMed PMID: 12417686]
[16]
Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in neurosciences. 1998 Dec:21(12):521-8
[PubMed PMID: 9881850]
[17]
Nallapaneni A, Liu J, Karanth S, Pope C. Pharmacological enhancement of endocannabinoid signaling reduces the cholinergic toxicity of diisopropylfluorophosphate. Neurotoxicology. 2008 Nov:29(6):1037-43. doi: 10.1016/j.neuro.2008.08.001. Epub 2008 Aug 13
[PubMed PMID: 18765251]
[18]
Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacological research. 2009 Aug:60(2):85-92. doi: 10.1016/j.phrs.2009.03.019. Epub 2009 Apr 7
[PubMed PMID: 19428268]
[19]
Mouhamed Y,Vishnyakov A,Qorri B,Sambi M,Frank SS,Nowierski C,Lamba A,Bhatti U,Szewczuk MR, Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. Drug, healthcare and patient safety. 2018;
[PubMed PMID: 29928146]
[21]
Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, Huestis MA. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. Clinical chemistry. 2015 Jun:61(6):850-69. doi: 10.1373/clinchem.2015.238287. Epub 2015 May 27
[PubMed PMID: 26019183]
[22]
Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. The New England journal of medicine. 2014 Jun 5:370(23):2219-27. doi: 10.1056/NEJMra1402309. Epub
[PubMed PMID: 24897085]
[23]
Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nature reviews. Neuroscience. 2016 May:17(5):293-306. doi: 10.1038/nrn.2016.28. Epub 2016 Apr 7
[PubMed PMID: 27052382]
[24]
Joshi M, Joshi A, Bartter T. Marijuana and lung diseases. Current opinion in pulmonary medicine. 2014 Mar:20(2):173-9. doi: 10.1097/MCP.0000000000000026. Epub
[PubMed PMID: 24384575]
Level 3 (low-level) evidence
[25]
de Graaf R, Radovanovic M, van Laar M, Fairman B, Degenhardt L, Aguilar-Gaxiola S, Bruffaerts R, de Girolamo G, Fayyad J, Gureje O, Haro JM, Huang Y, Kostychenko S, Lépine JP, Matschinger H, Mora ME, Neumark Y, Ormel J, Posada-Villa J, Stein DJ, Tachimori H, Wells JE, Anthony JC. Early cannabis use and estimated risk of later onset of depression spells: Epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative. American journal of epidemiology. 2010 Jul 15:172(2):149-59. doi: 10.1093/aje/kwq096. Epub 2010 Jun 9
[PubMed PMID: 20534820]
Level 3 (low-level) evidence
[26]
Blanco C, Hasin DS, Wall MM, Flórez-Salamanca L, Hoertel N, Wang S, Kerridge BT, Olfson M. Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study. JAMA psychiatry. 2016 Apr:73(4):388-95. doi: 10.1001/jamapsychiatry.2015.3229. Epub
[PubMed PMID: 26886046]
[28]
Beaulieu P, Boulanger A, Desroches J, Clark AJ. Medical cannabis: considerations for the anesthesiologist and pain physician. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 2016 May:63(5):608-24. doi: 10.1007/s12630-016-0598-x. Epub 2016 Feb 5
[PubMed PMID: 26850063]
[30]
Crippa JA, Derenusson GN, Chagas MH, Atakan Z, Martín-Santos R, Zuardi AW, Hallak JE. Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm reduction journal. 2012 Jan 25:9():7. doi: 10.1186/1477-7517-9-7. Epub 2012 Jan 25
[PubMed PMID: 22273390]
Level 1 (high-level) evidence